Matt Meyerson headshot

Matt Meyerson

Charles A. Dana Chair in Human Cancer Genetics, Dana-Farber Cancer Institute
Professor of Genetics and Medicine, Harvard Medical School
Director, Center for Cancer Genomics, Dana-Farber Cancer Institute
Dana Farber Cancer Institute
617-632-4377
Meyerson Lab
Genomic approaches to lung cancer.
Authors: Authors: Thomas RK, Weir B, Meyerson M.
Clin Cancer Res
View full abstract on Pubmed
Epidermal growth factor receptor mutation testing in the care of lung cancer patients.
Authors: Authors: Sequist LV, Joshi VA, Jänne PA, Bell DW, Fidias P, Lindeman NI, Louis DN, Lee JC, Mark EJ, Longtine J, Verlander P, Kucherlapati R, Meyerson M, Haber DA, Johnson BE, Lynch TJ.
Clin Cancer Res
View full abstract on Pubmed
Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents.
Authors: Authors: Lynch TJ, Adjei AA, Bunn PA, Eisen TG, Engelman J, Goss GD, Haber DA, Heymach JV, Jänne PA, Johnson BE, Johnson DH, Lilenbaum RC, Meyerson M, Sandler AB, Sequist LV, Settleman J, Wong KK, Hart CS.
Clin Cancer Res
View full abstract on Pubmed
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
Authors: Authors: Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, Jänne PA.
Clin Cancer Res
View full abstract on Pubmed
Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.
Authors: Authors: Shimamura T, Ji H, Minami Y, Thomas RK, Lowell AM, Shah K, Greulich H, Glatt KA, Meyerson M, Shapiro GI, Wong KK.
Cancer Res
View full abstract on Pubmed
Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing.
Authors: Authors: Thomas RK, Nickerson E, Simons JF, Jänne PA, Tengs T, Yuza Y, Garraway LA, LaFramboise T, Lee JC, Shah K, O'Neill K, Sasaki H, Lindeman N, Wong KK, Borras AM, Gutmann EJ, Dragnev KH, DeBiasi R, Chen TH, Glatt KA, Greulich H, Desany B, Lubeski CK, Brockman W, Alvarez P, Hutchison SK, Leamon JH, Ronan MT, Turenchalk GS, Egholm M, Sellers WR, Rothberg JM, Meyerson M.
Nat Med
View full abstract on Pubmed
Epidermal growth factor receptor (EGFR) mutation testing in non-small cell lung cancer (NSCLC) patients (pts).
Authors: Authors: Sequist LV, Joshi VA, Jänne PA, Fidias P, Muzikansky A, Meyerson M, Haber DA, Kucherlapati R, Johnson BE, Lynch TJ.
J Clin Oncol
View full abstract on Pubmed
Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors.
Authors: Authors: Ji H, Zhao X, Yuza Y, Shimamura T, Li D, Protopopov A, Jung BL, McNamara K, Xia H, Glatt KA, Thomas RK, Sasaki H, Horner JW, Eck M, Mitchell A, Sun Y, Al-Hashem R, Bronson RT, Rabindran SK, Discafani CM, Maher E, Shapiro GI, Meyerson M, Wong KK.
Proc Natl Acad Sci U S A
View full abstract on Pubmed
Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays.
Authors: Authors: Beroukhim R, Lin M, Park Y, Hao K, Zhao X, Garraway LA, Fox EA, Hochberg EP, Mellinghoff IK, Hofer MD, Descazeaud A, Rubin MA, Meyerson M, Wong WH, Sellers WR, Li C.
PLoS Comput Biol
View full abstract on Pubmed
Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor.
Authors: Authors: Alvarez JV, Greulich H, Sellers WR, Meyerson M, Frank DA.
Cancer Res
View full abstract on Pubmed